マルタ - 英語 - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/5ml - antineoplastic agents

カナダ - 英語 - Health Canada

fresenius kabi canada ltd - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents

イスラエル - 英語 - Ministry of Health

abic marketing ltd, israel - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - etoposide - etoposide - hodgkin's disease. malignant (non-hodgkin's) lymphomas, especially of the histiocytic variety.acute non-lymphocytic leukemia. management of refractory testicular tumors and of small cell lung cancer.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

bluepoint laboratories - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml - etoposide injection usp is indicated in the management of the following neoplasms: etoposide injection usp in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. etoposide injection usp in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide injection usp is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

accord healthcare inc. - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml - etoposide injection usp is indicated in the management of the following neoplasms: etoposide injection usp in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. etoposide injection usp in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide injection usp is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml - etoposide injection, usp is indicated in the management of the following neoplasms: etoposide injection, usp in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. adequate data on the use of etoposide capsules in the treatment of testicular cancer are not available. etoposide injection, usp and/or capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide injection, usp is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

accord healthcare inc. - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml - etoposide injection usp is indicated in the management of the following neoplasms: etoposide injection usp in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. etoposide injection usp in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide injection usp is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 50 mg - etoposide capsules are indicated in the management of the following neoplasms: etoposide capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml - etoposide injection, usp is indicated in the management of the following neoplasms: etoposide injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. etoposide injection and/or capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. etoposide is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.